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Abstract
Background: RBM3 expression has been suggested as prognostic marker in several cancer types. The purpose of
this study was to assess the prevalence and clinical significance of altered RBM3 expression in esophageal cancer.
Methods: RBM3 protein expression was measured by immunohistochemistry using tissue microarrays containing
samples from 359 esophageal adenocarcinoma (EAC) and 254 esophageal squamous cell cancer (ESCC) patients
with oncological follow-up data.
Results: While nuclear RBM3 expression was always high in benign esophageal epithelium, high RBM3 expression
was only detectable in 66.4% of interpretable EACs and 59.3% of ESCCs. Decreased RBM3 expression was linked to a
subset of EACs with advanced UICC stage and presence of distant metastasis (P = 0.0031 and P = 0.0024). In ESCC,
decreased RBM3 expression was associated with advanced UICC stage, high tumor stage, and positive lymph node
status (P = 0.0213, P = 0.0061, and P = 0.0192). However, RBM3 expression was largely unrelated to survival of
patients with esophageal cancer (EAC: P = 0.212 and ESCC: P = 0.5992).
Conclusions: In summary, the present study shows that decreased RBM3 expression is associated with
unfavourable esophageal cancer phenotype, but not significantly linked to patient prognosis.
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Background
Esophageal cancer is one of the most aggressive can-
cers and is the sixth leading cause of cancer death
worldwide. Currently, there are limited clinical ap-
proaches for the early diagnosis and treatment of
esophageal cancer, resulting in only a 10% five-year
survival rate for patients. It can be hoped, that the
identification of novel biological markers and tumori-
genic pathways will improve therapeutic strategies for
esophageal cancer patients.
RBM3 is a glycine-rich RNA-binding protein and
part of the family of cold shock proteins [1]. Proteins
from this family are induced by various environmental
stresses, including hypoxia [2] and cold [2–4]. RBM3
bind to DNA and RNA [5] and is involved in main-
tenance of DNA integrity, including DNA-dependent
replication, DNA replication, chromatin remodeling,
DNA integrity checkpoints [6] and regulation of RNA
metabolism, including splicing, stability and transport
of mRNA [1].
In cancer there are multiple contradictory reports re-
garding the role and expression of RBM3. RBM3 has been
suggested to have potential proto-oncogene and tumor
suppressive roles in cancer. RBM3 expression leads to the
synthesis of proteins associated with survival and
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proliferation [7–9] and to the synthesis of proteins associ-
ated with apoptosis [10]. Using immunohistochemistry,
dysregulated RBM3 expression has been suggested as
prognostic biomarker in several cancers [11–19].
Only one immunohistochemical study has so far ana-
lysed RBM3 expression in upper gastrointestinal adeno-
carcinomas using a tissue microarray containing of 175
tumor specimens [12]. The authors suggested a potential
prognostic role of altered RBM3 expression in patients
with upper gastrointestinal adenocarcinomas [12]. To
better assess the role of RBM expression in esophageal
cancers, immunohistochemistry was applied to tissue
microarrays containing samples from more than 600
esophageal cancer patients with oncological follow-up
data. The present study shows that decreased RBM3 ex-
pression is linked to a subset of esophageal cancers with
unfavourable tumor phenotype.
Methods
Patients, follow-up, and TMA construction
Two TMA were constructed from cancer tissues from
359 EAC and 254 ESCC patients who underwent surgery
at the University Medical Center Hamburg-Eppendorf.
Follow-up data were available of 359 EAC and 254
ESCC patients with a median follow-up of 17.3 and
12.2 months (range: 0 to 208 and 0 to 191 months). All
esophageal specimens were analyzed according to a
standard procedure, including complete embedding of
the entire esophagus for histological analysis. The TMA
manufacturing process was described earlier in detail
[20]. In short, one 0.6 mm core was taken from a repre-
sentative tissue block from each patient. The tissues
were distributed among 2 TMA blocks. For internal con-
trols, each TMA block also contained various control
tissues, including normal esophageal tissue.
Immunohistochemistry
For Immunohistochemistry, slides were deparaffinized and
exposed to heat-induced antigen retrieval for 5 min in an
autoclave at 121 C in pH 7.8 Tris- EDTA- Citrate buffer.
Primary antibody specific for RBM3 (polyclonal rabbit,
HPA003624; Sigma–Aldrich; at 1/150 dilution) was applied
at 37 °C for 60 min. Bound antibody was then visualized
using the EnVision Kit (Dako, Glostrup, Denmark) accord-
ing to the manufacturer instructions. Since nuclear staining
was typically paralleled by similar or slightly lower cytoplas-
mic staining, only nuclear staining was considered. For stat-
istical analyses, the staining results were categorized in two
groups: low and high RBM3 immunostaining.
Statistical analysis
Statistical calculations were done with JMP® software
(SAS Institute Inc., NC, USA). Contingency tables were
performed to search for associations between molecular
parameters and tumor phenotype. Chi-square (Likeli-
hood) test was employed to identify significant relation-
ships between these parameters. Survival curves were
calculated according to Kaplan–Meier. Log-Rank test
was applied to test for significant differences between
stratified survival curves. Cox proportional hazards re-
gression analysis was calculated to test the statistical in-
dependence and significance between pathological,
molecular and clinical variables.
Results
RBM3 immunostaining in esophageal cancers
A total of 268 of 359 (74.7%) of EAC and 226 of 254
(89%) of ESCC samples were interpretable for immuno-
histochemistry in our TMA analysis. Reasons for
non-informative cases included a complete lack of tissue
samples or absence of unequivocal cancer tissue in the
TMA section. RBM3 expression was high in benign
esophageal epithelium predominantly localized in the
nucleus of the cells. The expression levels of RBM3 were
homogenous in the analyzed spots. RBM3 expression
was found in decreased intensities in malignant as com-
pared to benign esophageal epithelium. In malignant
oesophagus, high RBM3 expression was only detectable
in 66.4% of 268 interpretable EAC and in 59.3% of 226
ESCC specimens. Figure 1 shows representative pictures
of RBM3 immunostaining in esophageal cancers and be-
nign squamous esophageal tissue.
Association with tumor phenotype and clinical outcome
The associations between RBM3 immunostaining and
tumor phenotype are depicted in Tables 1 and 2. De-
creased RBM3 expression was linked to a subset of
EACs with advanced UICC stage and presence of distant
metastasis (P = 0.0031 and P = 0.0024). In ESCC, de-
creased RBM3 expression was associated with advanced
UICC stage, high tumor stage, and positive lymph node
status (P = 0.0213, P = 0.0061, and P = 0.0192).
Follow-up data were available for 173 EAC and 166
ESCC patients with informative RBM3 data. RBM3 ex-
pression was not associated with overall survival of EAC
and ESCC patients (P = 0.212 and P = 0.5992). The rela-
tionship between RBM3 immunostaining intensity and
clinical outcome of the patients is shown in Fig. 2.
Association between RBM3 expression and p53
expression in esophageal cancers
To evaluate whether RBM3 expression is linked to p53
expression in esophageal cancer, our pre-existing data-
base including data on p53 immunostaining (unpub-
lished data) was used. Our results demonstrate that
RBM3 expression was unrelated to p53 expression in all
esophageal cancer samples (p = 0.1098), as well as the
subset of EACs (p = 0.8339) and ESCCs (p = 0.1466).
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Discussion
The data from this study show, that altered RBM3 ex-
pression – a strong prognostic feature in several cancer
types – is statistically linked to adverse tumor features in
oesophageal cancer but does not have an obvious impact
on clinical outcome.
The comparative analysis of normal and neoplastic
epithelium revealed that RBM3 expression was reduced
in a fraction of cancers. These results are in line with
data of one earlier study analyzing RBM3 expression in
60 EAC samples [12]. The authors also found a signifi-
cantly higher RBM3 expression in normal squamous epi-
thelium as compared to primary tumours [12].
Earlier studies on RBM3 expression in other malignan-
cies have often indicated a biological and clinical signifi-
cance of RBM3 expression, but results varied substantially
between tumor entities. An increase of RBM3 in malig-
nant relative to corresponding benign tissue has been sug-
gested in gastric [12], prostate [11, 17] and breast [19]
cancer. However, a decreased RBM3 expression in cancer-
ous relative to non-cancerous tissue has been reported in
colon cancer [21], malignant melanoma [16], and urothe-
lial bladder cancer [14]. These discrepant observations
may be due to different interactions between RBM3 and
other gene products expressed and activated in individual
tissue types.
In vitro studies on the role of RBM proteins in tumori-
genesis have also yielded conflicting results and the exact
function of RBM3 is still to be fully elucidated. So far,
pro-oncogenic as well as tumor suppressive functions of
RBM3 have been suggested [6, 10, 22, 23]. Some studies
suggested RBM3 to induce cell proliferation and inhibit
Fig. 1 Representative images of RBM3 immunostaining in oesophageal
cancer. The image shows low and high RBM3 immunostaining in EACs
(a and b) and ESCCs (c and d). Image of RBM3 immunostaining in
benign squamous esophageal tissue (e)
Table 1 Association of RBM3 IHC results and clinico-
pathological features of esophageal adenocarcinoma samples
RBM3 immunohistochemistry
Analyzable, n Low, % High, % p value
All cancers 268 33.58 66.42
Age group
< 65 years 84 65.76 34.24 0.7355
> 65 years 184 67.86 32.14
Sex
male 226 33.63 66.37 0.9703
female 42 33.33 66.67
Tumor stage
pT1 55 23.64 76.36 0.333
pT2 28 35.71 64.29
pT3 163 36.81 63.19
pT4 20 35 65
UICC stage
I 52 19.23 80.77 0.0031
II 36 30.56 69.44
III 155 34.84 65.16
IV 24 62.5 37.5
Tumor grading
G1 14 21.43 78.57 0.6477
G2 98 35.71 64.29
G3 150 33.33 66.67
G4 4 50 50
Resektion margin
R0 193 34.72 65.28 0.4129
R1 69 30.43 69.57
R2 3 66.67 33.33
Lymph node metastasis
N0 82 24.39 75.61 0.1623
N1 43 34.88 65.12
N2 65 41.54 58.46
N3 75 34.67 65.33
Distant metastasis
M0 244 30.74 69.26 0.0024
M1 24 62.5 37.5
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the DNA damage response machinery and cell death [6,
22, 23], while others suggested RBM3 to be positive asso-
ciated with the pro-apoptotic BAX gene [10], to be down-
regulated in an in vitro model of melanoma progression
[24], and to enhance platinum-sensitivity in vitro in ovar-
ian cancer [18]. Our finding of reduced RBM3 expression
being associated with advanced tumor stage in adenocar-
cinoma of the esophagus is supported by findings of
Jonsson et al. [12] describing a significant association be-
tween reduced RBM3 expression and a more aggressive
tumor phenotype. Our data further suggest, that RBM3
might play a comparable role in squamous cell carcin-
omas. In this subset of esophageal cancers, reduced RBM3
expression was statistically linked to adverse tumor fea-
tures. The fact that reduced RBM3 expression was linked
to development of cancer and was associated with adverse
tumor features in our study suggests a tumor suppressive
rather than an oncogenic role in esophageal cancers. Pre-
viously, studies have shown that BAX also plays a critical
role in the determination of tumor response to radiation
therapy in esophageal carcinoma cells [25]. Thus, it can be
speculated that RBM3 might be also associated to the ex-
pression of pro-apoptotic BAX gene in our study. How-
ever, the exact mechanism how reduced RBM3 dives
esophageal carcinogenesis remains elusive.
However, in our study, RBM3 expression loss has no
clinically relevant impact on patient prognosis in both
entities. These data disagree with the study of Jonsson et
al. [12] suggesting RBM3 expression as a relevant prog-
nostic marker in a mixed cohort of gastric and esopha-
geal adenocarcinomas. These discrepant results may be
due to differences in the patient cohorts. We only in-
cluded esophageal cancer patients in our study. It can be
speculated that the prognostic impact of RBM3 expres-
sion in the Jonsson’s mixed cohort of upper gastrointes-
tinal adenocarcinomas, was largely driven by the subset
of gastric cancers.
To evaluate whether RBM3 expression is linked to p53
expression in esophageal cancer, our pre-existing data-
base on p53 immunostaining was used. In general, the
pathogenesis of esophageal carcinoma is highly complex,
involving an accumulation of genetic modifications
resulting in invasive carcinoma [26, 27]. Genetic muta-
tions within the tumour suppressor gene, TP53, which is
involved in DNA repair and cell cycle arrest [26, 28, 29],
is one of the most frequently genetic abnormalities in
cancers [30]. Thus, we next correlated RBM3 expression
with pre-existing data on p53 IHC in esophageal cancer.
Our results demonstrate that RBM3 expression was un-
related to p53 expression in esophageal cancer samples.
Previously, authors speculated that the analysis of sig-
nificances between biomarkers and clinical outcome is
limited due to tumour heterogeneity [31] and that the
analysis of multiple cores per tumor specimen might en-
hance the representativity of TMA studies [32]. These
authors suggest that there might exist a better concord-
ance of large section findings with tissue microarrays
data, if 3–4 cores were analysed per cancer on compari-
son to the use of only one core. However, these sugges-
tions were based on the assumption that significant
heterogeneity may exist within the tissue represented by
a standard 3 × 4 cm paraffin block, and that large section
Table 2 Association of RBM3 IHC results and clinico-
pathological features of esophageal squamous cell carcinoma
samples
RBM3 immunohistochemistry
Analyzable, n Low, % High, % P value
All cancers 226 40.71 59.29
Age group
< 65 years 86 46.51 53.49 0.178
> 65 years 139 37.41 62.59
Sex
male 160 41.88 58.13 0.6362
female 65 38.46 61.54
Tumor stage
pT1 40 17.5 82.5 0.0061
pT2 46 41.3 58.7
pT3 126 46.83 53.17
pT4 14 50 50
UICC stage
I 55 23.64 76.36 0.0213
II 57 45.61 54.39
III 102 47.06 52.94
IV 10 50 50
Tumor grading
G1 3 33.33 66.67 0.3216
G2 141 44.68 55.32
G3 81 34.57 65.43
G4 0 0 0
Resektion margin
R0 168 39.29 60.71 0.0717
R1 47 40.43 59.57
R2 9 77.78 22.22
Lymph node metastasis
N0 100 35 65 0.0192
N1 55 32.73 67.27
N2 40 55 45
N3 29 58.62 41.38
Distant metastasis
M0 216 59.72 40.28 0.366
M1 9 44.44 55.56
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analysis is the method of choice to estimate tumor het-
erogenity. In our opinion, this assumption is disputable,
since previously, data have shown that the TMA format
is generally superior over large section studies to analyse
potential correlations between molecular markers and
the clinical outcome [33] and that there were found high
significances between biomarkers and clinical outcome
irrespectively if the three tissue cores were analyzed sep-
arately, or if a combined result was generated from the
three cores [34]. These data demonstrate that the use of
multiple cores in a TMA does not necessarily enhance
the ability to identify significant relationships between
biomarkers and tumor phenotype and/or prognosis.
Moreover, these data underline the robustness of IHC
microtissue array studies for analysis of correlations of
molecular markers with clinico-pathological features of
cancer specimens.
In summary, our data show that decreased RBM3 ex-
pression is associated with unfavourable esophageal can-
cer phenotype but is unrelated to prognosis of patients.
Therefore, RBM3 cannot be considered as a clinically
relevant prognostic biomarker in esophageal cancers.
Conclusions
In summary, the present study shows that decreased
RBM3 expression is associated with unfavourable
oesophageal cancer phenotype, but does not predict pa-
tients’ prognosis.
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